Here we describe results of the technical evaluation study of the therascreen PITX2 RGQ PCR assay according to Clinical and Laboratory Standards Institute (Clinical and Laboratory Standards Institute - CLSI; https://clsi.org/) guidelines for lymph node positive, ER positive, HER2 negative breast cancers. This evidence concerns the gene ERBB2 and breast cancer.